Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in neurology and allied disciplines.
Chapter 2: Neurobiology of Placebo: Interpreting Its Evolutionary Origin, Meaning, Mechanisms, Monitoring, and Implications in Therapeutics
Chapter 3: Role of Gut Microbiota in Neuroinflammation and Neurological Disorders
Chapter 4: The Role of Age in Pediatric Tumors of the Central Nervous System
Chapter 5: Drug Repurposing in CNS and Clinical Trials: Recent Achievements and Perspectives Focusing on Epilepsy and Related Comorbidities
Chapter 6: Progress on the Development of Oxime Derivatives as a Potential Antidote for Organophosphorus Poisoning
The twelfth volume of this series features these reviews:
Chapter 1: Recent Drugs Tested in Clinical Trials for Alzheimer's and Parkinson's Diseases Treatment: Current Approaches in Tracking New DrugsChapter 2: Neurobiology of Placebo: Interpreting Its Evolutionary Origin, Meaning, Mechanisms, Monitoring, and Implications in Therapeutics
Chapter 3: Role of Gut Microbiota in Neuroinflammation and Neurological Disorders
Chapter 4: The Role of Age in Pediatric Tumors of the Central Nervous System
Chapter 5: Drug Repurposing in CNS and Clinical Trials: Recent Achievements and Perspectives Focusing on Epilepsy and Related Comorbidities
Chapter 6: Progress on the Development of Oxime Derivatives as a Potential Antidote for Organophosphorus Poisoning
Readership
Pharmaceutical scientists, clinical researchers, medical consultants and allied healthcare professionals interested in neuropharmacology and neurologyTable of Contents
CHAPTER 1 RECENT DRUGS TESTED IN CLINICAL TRIALS FOR ALZHEIMER´S AND- PARKINSON´S DISEASES TREATMENT: CURRENT APPROACHES IN TRACKING NEW
- DRUGS
- Fernanda Majolo, Lavynia Ferreira Hoffmann, Wilian Luan Pilatti Sant’Ana, Celso
- Alves, Joana Silva, Alice Martins, Rui Pedrosa, Bruno Dahmer, Guilherme Liberato
- da Silva, Luís Fernando Saraiva Macedo Timmers and Márcia Inês Goettert
- INTRODUCTION
- ALZHEIMER'S DISEASE
- Etiopathogenesis and Physiopathology
- Diagnosis
- Treatment - Approved Drugs
- Prevention
- Clinical Trials
- Donepezil
- Methylphenidate
- Rivastigmine
- Suvorexant
- Zolpidem
- Zopiclone
- AXS-05
- Umibecestat (CNP520)
- PARKINSON'S DISEASE
- Etiopathogenesis and Physiopathology
- Diagnosis
- Treatment - Approved Drugs
- Prevention
- Clinical Trials
- Inosine
- LY03003
- Pimavanserin
- Droxidopa
- Pramipexole
- Opicapone (BIA 9-1067)
- Safinamide
- DA-9701
- NATURE AS A VALUABLE SOURCE OF CHEMICAL ENTITIES FOR PD AND AD
- THERAPEUTICS
- FUTURE ADVANCES IN THE FIELD - TRACKING NEW DRUGS
- CONCLUDING REMARKS
- REFERENCES
- ORIGIN, MEANING, MECHANISMS, MONITORING, AND IMPLICATIONS IN
- THERAPEUTICS
- Akash Marathakam, Vimal Mathew and MK Unnikrishnan
- INTRODUCTION
- The Context of Health and Disease: The Mind-Body Continuum
- Placebo and the Therapeutic Context: the Evolutionary Backdrop
- Measuring the Placebo Effect
- The Physiology of Placebo: Mechanistic Aspects
- Placebo Effect (PE): A Distraction in Clinical Trials [62]
- Leveraging the Placebo Effect
- CONCLUSION
- REFERENCES
- NEUROLOGICAL DISORDERS
- Khadga RajNavneet Arora, Rohit, Anupam Awasthi, Mayank Patel, Ankit ,
- Chaudhary, Shamsher Singh and G.D. Gupta
- INTRODUCTION
- COMPOSITION AND STRUCTURE OF THE HUMAN GI MICROBIOTA
- INTERACTION OF GUT AND NERVOUS SYSTEM, GUT-BRAIN-AXIS
- MICROBIAL METABOLITES AND CELLULAR COMPONENTS ON CNS
- MICROBIOTA AND NEURODEVELOPMENT
- MICROBIOTA AND AGEING
- MICROBIOTA AND NEUROINFLAMMATION
- Alzheimer’s Disease
- Impact of Gut Microbiota on Brain
- Role of Gut Microbiota in AD
- Probiotics
- Depression
- Clinical Features
- Classification, Prevalence, and Course of Depression
- Risk Factor for Depression
- Genetic Influences
- Biochemical Basis of Depression
- Synaptic Transmission
- Monoamine Hypothesis
- Transporters for Neurotransmitter Reuptake
- Impact of Gut Microbiota in Depression
- Gut Dysbiosis Association with Antidepressant Drugs
- How Gut Microbiota Alters in Depression
- Parkinson’s Disease
- Clinical Features of PD
- Pathology/Etiology
- Mechanisms of Neurodegeneration in PD
- Role of Gut Microbiota in PD
- Current Pharmacotherapy to Treat PD
- Microbiota Targeted Strategies to Control PD
- Multiple Sclerosis
- Clinical Features
- Pathology
- Mechanisms of Demyelination and Axonal Dysfunction in MS
- Role of Gut Microbiota in MS
- Diet and Gut Microbiota in Multiple Sclerosis
- The Role of Microbiota in Multiple Sclerosis: Clinical Trials
- Current Pharmacotherapy to Treat MS
- Targeting Gut Microbiome to Treat MS
- Autism Spectrum Disorder
- Pathomechanism of ASD
- The Gut Microbiome's Role in ASD's Underlying Mechanisms
- Role of Gut Microbiota in ASD
- The Therapeutic Perspective of ASD by Targeting Gut Microbiota
- CONCLUSION
- REFERENCES
- SYSTEM
- Nesibe S. Kutahyalioglu and Dylan V. Scarton
- INTRODUCTION
- Definition of Pediatric Tumors in the CNS
- Overview of the Current State of the Field
- Key Evidence-Based Factors Impacting Patients Outcomes
- CLINICAL ASPECTS
- Diagnosis and Screening
- Treatment Considerations and Management of Side Effects
- Long-Term Outcomes and Quality of Life
- AGE-RELATED TRENDS
- Importance of Understanding the Role of Age in the 0-14 Years Range
- Importance of Understanding the Role of Age for 14-21 Years Range
- MULTIDISCIPLINARY HEALTHCARE TEAMS
- Role of Collaboration
- Roles of Multidisciplinary Care Team During Diagnosis
- Roles of Multidisciplinary Care Team During Treatment
- Roles of Multidisciplinary Care Team After Treatment
- Effective Teamwork and Clinical Management
- Patient-and-Family Centered Care
- CONCLUSION
- Summary of Findings
- Future Directions for Research
- Implications for Clinical Practice and Patient Care
- REFERENCES
- ACHIEVEMENTS AND PERSPECTIVES FOCUSING ON EPILEPSY AND RELATED
- COMORBIDITIES
- Gabriela Machado Parreira, Antonio Carlos Pinheiro de Oliveira, Leonardo de Oliveira
- Guarnieri and Rafael Pinto Vieira
- INTRODUCTION
- The Drug Repurposing Context
- Drug Repurposing Aiming at Cognitive Improvement and Anticonvulsant Activity in
- Epilepsy
- Memantine
- Methylphenidate
- Natalizumab
- Everolimus
- Melatonin
- Digoxin
- DEPRESSION: INTERFACE WITH EPILEPSIES IN A DRUG REPURPOSING
- CONTEXT
- Ketamine
- Infliximab
- Minocycline
- Fluoxetine and Escitalopram
- CONCLUSION
- ACKNOWLEDGEMENTS
- REFERENCES
- POTENTIAL ANTIDOTE FOR ORGANOPHOSPHORUS POISONING
- Manjunatha S. Katagi, M.L Sujatha, Girish Bolakatti, B.P. Nandeshwarappa, S.N.
- Mamledesai and Jennifer Fernandes
- INTRODUCTION
- History
- Organophosphorus Compounds
- General Structure Of An OP
- Classification of OP Compounds [19 - 23]
- OP Poisoning
- Mechanism of Toxicity
- Pharmacokinetics Of Organophosphorus Compounds [42-44]
- Clinical Features of Organophosphorus Poisoning
- Management and Treatment [19, 20, 46]
- Muscarinic Antagonist Drug
- Oxime As Acetylcholinesterase Reactivator
- Structure Activity Relationships
- Other Therapies
- Others
- Design And Synthesis Of New AChE Reactivators
- DISCUSSION
- CONCLUSION AND OUTLOOK
- ACKNOWLEDGEMENTS
- REFERENCES
- SUBJECT INDEX
Author
- Zareen Amtul
